Form 4: Turnstone Biologics Director Acquires Stock Options

Director Robert J. Gould acquired 12,770 stock options in Turnstone Biologics Corp. on June 3, 2024.

Summary

• Robert J. Gould, a director of Turnstone Biologics Corp., reported a transaction involving the acquisition of stock options.
• The transaction occurred on June 3, 2024.
• Gould acquired 12,770 stock options with an exercise price of $2.69.
• The options vest on the earlier of June 3, 2025, or the date of the next annual meeting of stockholders, contingent upon continuous service.
• The options expire on June 2, 2034.
• Following the transaction, Gould directly owns 12,770 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports an insider transaction. The acquisition of stock options by a director could be interpreted as a positive sign, but without further context, it's difficult to gauge the overall impact.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC when a company insider, such as a director, engages in a transaction involving the company's securities. It provides transparency to the market regarding insider activity.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals confidence from a company director.

Key Dates

Keywords

stock options, Form 4, insider trading, Turnstone Biologics, TSBX, Robert J. Gould, director